Written by the Nuvirox Research Team
Short answer: promising in mice, completely untested in people. Several animal studies link NAD+ decline to age-related bone loss through a specific cellular pathway, and nicotinamide riboside slowed osteoporosis progression in mice — but no published human trial has measured NAD+ precursors and bone density.
Key Points
- Aging osteoblast progenitor cells (the cells that build new bone) show measurably lower NAD+ levels, tied to a specific pathway involving the enzyme SIRT1.
- In mice, long-term NR supplementation starting in midlife slowed the pace of age-related osteoporosis.
- No human trial has measured bone mineral density, fracture risk, or bone turnover markers after NAD+ precursor supplementation.
The mouse-level mechanism
Bone is constantly being broken down and rebuilt by two cell types working in opposition: osteoclasts (which resorb old bone) and osteoblasts (which build new bone). Osteoporosis develops when that balance tips toward resorption — often because the supply of new, functional osteoblasts declines. Research has traced part of that decline to aging osteoblast progenitor cells accumulating lower NAD+ levels, which reduces activity of the NAD+-dependent enzyme SIRT1. Less SIRT1 activity means less suppression of FoxO transcription factors, which in turn dampens Wnt/β-catenin signaling — a pathway essential for progenitor cells to actually become new, bone-building osteoblasts.
In a mouse study, researchers found that long-term nicotinamide riboside supplementation starting in midlife — and continuing into old age — measurably slowed the pace of osteoporosis compared to untreated aging mice, consistent with this mechanism. A separate line of research found that NR also protected against bone loss induced by diabetes in mice, through improving mitochondrial oxidative phosphorylation (OXPHOS) in bone cells.
What's missing: any human data at all
This is a case where the animal evidence is genuinely well-developed and mechanistically coherent, but the translation to humans simply hasn't been tested yet. Searching the human NAD+ precursor trial literature — which includes dozens of published RCTs on cardiovascular, metabolic, muscle, and safety outcomes — turns up no trial that measured bone mineral density (via DEXA scan), fracture incidence, or bone turnover markers (like CTX or P1NP) as an outcome.
A broader review that critically assessed the 25 published human trials of nicotinamide riboside concluded that, collectively, oral NR supplementation has displayed few clinically relevant effects, and cautioned against the literature's tendency to exaggerate the robustness of reported benefits [1]. Bone health wasn't even among the outcomes those 25 trials measured — it's simply outside the current human evidence base.
What NAD+ won't do
NAD+ precursors are not a treatment for osteoporosis or low bone density, and nothing in the current evidence supports using them in place of established approaches — adequate calcium and vitamin D intake, weight-bearing exercise, and, where appropriate, prescribed osteoporosis medications. If you've had a DEXA scan showing low bone density, or you're at higher risk (postmenopausal, family history, long-term steroid use, certain other medications), that's a conversation to have directly with your doctor about a bone-health-specific plan.
A fair way to hold this evidence
The mouse data here is a genuinely interesting early signal — the cellular pathway is specific and well-characterized, not just a vague "NAD+ helps everything" claim. But mouse-to-human translation fails more often than it succeeds across supplement research generally, and bone remodeling in particular operates on a years-long timescale that's hard to model faithfully in short-lived rodents. Until a human trial actually measures bone outcomes, this belongs in the "worth watching" category, not the "supported by evidence" category.
Frequently asked questions
Can NAD+ supplements prevent osteoporosis?
There's no human evidence for this. The pathway is well-studied in mice, where NR supplementation slowed age-related bone loss, but no human trial has tested bone density or fracture outcomes.
Is this connection just marketing, or is there real science behind it?
There's real, specific cell biology behind it — a defined pathway involving NAD+, SIRT1, and bone-forming cells. The gap is that this hasn't been confirmed in human bone outcomes yet, which is a meaningful and honest limitation.
What actually works for bone density?
Adequate calcium and vitamin D, regular weight-bearing and resistance exercise, not smoking, moderate alcohol intake, and — for diagnosed osteoporosis — prescription medications your doctor can discuss with you.
Should I get a bone density scan?
If you're postmenopausal, over 65, or have risk factors like a family history of osteoporosis or long-term steroid use, talk to your doctor about whether a DEXA scan is appropriate for you.
Bone and muscle aging are closely linked processes — our article on NAD+ and muscle loss covers the related sarcopenia research, and our companion piece on NAD+ and joint pain looks at the parallel cartilage research using a similar mitochondrial mechanism.
Would a higher dose of NAD+ precursors work better for bone health?
There's no dose-response data for bone outcomes specifically since no human trial has tested this endpoint at any dose. The doses used in other human trials (500–1,000 mg/day NR) haven't been evaluated for bone-specific effects.
The diabetes-related bone loss research adds a second, independent data point to the mouse evidence: in high-fat-diet and streptozotocin-induced diabetic mice, nicotinamide riboside was found to protect against bone loss specifically by restoring oxidative phosphorylation (OXPHOS) that diabetes had disrupted in bone cells, working through a related pathway (upregulating Sirt2/FOXO3A while downregulating NF-κB signaling tied to bone resorption). That two independent mouse models — age-related bone loss and diabetes-related bone loss — point toward a similar NAD+-dependent mechanism is a reasonably coherent preclinical story. It still doesn’t substitute for the human trial that hasn’t been run.
It’s also worth remembering that bone remodeling in humans happens on a multi-year timescale, since a full remodeling cycle in adult bone takes several months on its own. Even a well-designed human trial would likely need a year or more of follow-up, with DEXA scans at baseline and endpoint, to detect a real change in bone mineral density — a considerably bigger and more expensive undertaking than the 6-to-12-week trials that make up most of the current NAD+ precursor evidence base.
From Nuvirox
Why we formulated NAD+ Restore
If what you're dealing with sounds like it belongs in a doctor's office rather than a supplement aisle, please start there — a clinician can rule out the specific causes discussed above. For general cellular energy support, each serving of NAD+ Restore provides 500 mg of nicotinamide riboside chloride (NR), one of the two most-researched NAD+ precursors, within the dose range used in published human trials, alongside 150 mg trans-resveratrol and 50 mg quercetin (polyphenols studied alongside NAD+ pathways for cellular health support) and 10 mg of galactomannans from fenugreek to support absorption.
We back it with a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
Learn more about NAD+ Restore →The bottom line
This is a clean example of promising preclinical science that hasn't yet been tested where it matters most: in people. The cellular pathway connecting NAD+ decline to reduced bone formation is specific and mechanistically sound, and it held up in a mouse model of aging. But no human trial has measured bone density, and until one does, this remains a hypothesis worth tracking rather than a supported benefit.
References
- Damgaard MV, Treebak JT. What is really known about the effects of nicotinamide riboside supplementation in humans. Sci Adv. 2023;9. doi:10.1126/sciadv.adi4862.
- Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286. doi:10.1038/s41467-018-03421-7.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.